05/11/2025
Did you know that three different versions of the human equivalent of Librela (tanezumab, fulranumab, and fasinumab) didn't make it through clinical trials because it was shown to actually speed up the progression of arthritis in some of the people who were participating in the trials? Zoetis, the company that makes Librela (bedinvetmab), only looked at 89 dogs over the course of 3 doses during it's preclinical trials, and they did not take any before and after radiographs to look at whether or not the arthritis was progressing.
The independent researchers in following article did, and it's no surprise here that the same thing is happening in dogs, and more! "Ligament/tendon injuries, polyarthritis, fractures, musculoskeletal neoplasia, and septic arthritis were reported nine times more frequently in Librela-treated dogs." And this is just the musculoskeletal issues. What's happening to the rest of the body like nerves and the immune system?
https://www.frontiersin.org/journals/veterinary-science/articles/10.3389/fvets.2025.1581490/full?fbclid=IwY2xjawKNtp5leHRuA2FlbQIxMQABHioFHuoeaq40cty3HWTBtvTOafTONTYBbEdHUGQDX8Nu9gmKCpqwAigO1RzH_aem_OMaxN4d3nipZvA4hfZxnIQ
